|
Gene: PRMT1 |
Gene summary for PRMT1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | PRMT1 | Gene ID | 3276 |
Gene name | protein arginine methyltransferase 1 | |
Gene Alias | ANM1 | |
Cytomap | 19q13.33 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | A0A087X1W2 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3276 | PRMT1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 2.58e-26 | 7.78e-01 | 0.294 |
3276 | PRMT1 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 5.58e-07 | 1.18e+00 | 0.3487 |
3276 | PRMT1 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 2.27e-11 | 5.31e-01 | 0.281 |
3276 | PRMT1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 5.63e-24 | 7.25e-01 | 0.3859 |
3276 | PRMT1 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 2.17e-09 | 5.62e-01 | 0.2585 |
3276 | PRMT1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 7.86e-16 | 4.83e-01 | 0.3005 |
3276 | PRMT1 | AEH-subject1 | Human | Endometrium | AEH | 4.19e-07 | -3.33e-01 | -0.3059 |
3276 | PRMT1 | AEH-subject2 | Human | Endometrium | AEH | 1.43e-08 | -3.60e-01 | -0.2525 |
3276 | PRMT1 | AEH-subject3 | Human | Endometrium | AEH | 4.78e-13 | -3.66e-01 | -0.2576 |
3276 | PRMT1 | AEH-subject4 | Human | Endometrium | AEH | 1.13e-10 | -4.38e-01 | -0.2657 |
3276 | PRMT1 | AEH-subject5 | Human | Endometrium | AEH | 1.21e-14 | -4.79e-01 | -0.2953 |
3276 | PRMT1 | EEC-subject1 | Human | Endometrium | EEC | 9.85e-22 | -3.99e-01 | -0.2682 |
3276 | PRMT1 | EEC-subject2 | Human | Endometrium | EEC | 2.45e-13 | -3.87e-01 | -0.2607 |
3276 | PRMT1 | EEC-subject3 | Human | Endometrium | EEC | 4.51e-41 | -4.92e-01 | -0.2525 |
3276 | PRMT1 | EEC-subject4 | Human | Endometrium | EEC | 3.70e-15 | -4.69e-01 | -0.2571 |
3276 | PRMT1 | EEC-subject5 | Human | Endometrium | EEC | 3.85e-15 | -4.19e-01 | -0.249 |
3276 | PRMT1 | GSM5276934 | Human | Endometrium | EEC | 4.56e-20 | 3.31e-01 | -0.0913 |
3276 | PRMT1 | GSM5276937 | Human | Endometrium | EEC | 1.63e-09 | 2.50e-01 | -0.0897 |
3276 | PRMT1 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 6.04e-36 | -4.65e-01 | -0.1869 |
3276 | PRMT1 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 4.62e-32 | -4.01e-01 | -0.1875 |
Page: 1 2 3 4 5 6 7 8 9 10 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0008380 | Colorectum | AD | RNA splicing | 169/3918 | 434/18723 | 3.59e-18 | 2.04e-15 | 169 |
GO:0034101 | Colorectum | AD | erythrocyte homeostasis | 51/3918 | 129/18723 | 1.07e-06 | 3.59e-05 | 51 |
GO:0030099 | Colorectum | AD | myeloid cell differentiation | 119/3918 | 381/18723 | 1.24e-06 | 4.01e-05 | 119 |
GO:0002262 | Colorectum | AD | myeloid cell homeostasis | 57/3918 | 157/18723 | 6.17e-06 | 1.56e-04 | 57 |
GO:0048872 | Colorectum | AD | homeostasis of number of cells | 87/3918 | 272/18723 | 1.16e-05 | 2.61e-04 | 87 |
GO:0030218 | Colorectum | AD | erythrocyte differentiation | 45/3918 | 120/18723 | 2.22e-05 | 4.39e-04 | 45 |
GO:0001701 | Colorectum | AD | in utero embryonic development | 110/3918 | 367/18723 | 2.36e-05 | 4.62e-04 | 110 |
GO:0051403 | Colorectum | AD | stress-activated MAPK cascade | 72/3918 | 239/18723 | 4.77e-04 | 5.25e-03 | 72 |
GO:0031098 | Colorectum | AD | stress-activated protein kinase signaling cascade | 74/3918 | 247/18723 | 4.80e-04 | 5.27e-03 | 74 |
GO:0045646 | Colorectum | AD | regulation of erythrocyte differentiation | 20/3918 | 47/18723 | 6.54e-04 | 6.75e-03 | 20 |
GO:0070302 | Colorectum | AD | regulation of stress-activated protein kinase signaling cascade | 58/3918 | 195/18723 | 2.21e-03 | 1.74e-02 | 58 |
GO:0032872 | Colorectum | AD | regulation of stress-activated MAPK cascade | 57/3918 | 192/18723 | 2.51e-03 | 1.92e-02 | 57 |
GO:1903706 | Colorectum | AD | regulation of hemopoiesis | 99/3918 | 367/18723 | 3.08e-03 | 2.28e-02 | 99 |
GO:0045637 | Colorectum | AD | regulation of myeloid cell differentiation | 61/3918 | 210/18723 | 3.17e-03 | 2.35e-02 | 61 |
GO:00083801 | Colorectum | SER | RNA splicing | 123/2897 | 434/18723 | 3.84e-12 | 8.41e-10 | 123 |
GO:00341011 | Colorectum | SER | erythrocyte homeostasis | 39/2897 | 129/18723 | 1.70e-05 | 5.11e-04 | 39 |
GO:00022621 | Colorectum | SER | myeloid cell homeostasis | 44/2897 | 157/18723 | 4.09e-05 | 1.03e-03 | 44 |
GO:00488721 | Colorectum | SER | homeostasis of number of cells | 65/2897 | 272/18723 | 1.70e-04 | 3.19e-03 | 65 |
GO:00302181 | Colorectum | SER | erythrocyte differentiation | 33/2897 | 120/18723 | 5.15e-04 | 7.30e-03 | 33 |
GO:00456461 | Colorectum | SER | regulation of erythrocyte differentiation | 16/2897 | 47/18723 | 1.29e-03 | 1.44e-02 | 16 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04922 | Colorectum | AD | Glucagon signaling pathway | 41/2092 | 107/8465 | 1.18e-03 | 7.75e-03 | 4.94e-03 | 41 |
hsa049221 | Colorectum | AD | Glucagon signaling pathway | 41/2092 | 107/8465 | 1.18e-03 | 7.75e-03 | 4.94e-03 | 41 |
hsa049222 | Colorectum | SER | Glucagon signaling pathway | 38/1580 | 107/8465 | 2.57e-05 | 3.28e-04 | 2.38e-04 | 38 |
hsa049223 | Colorectum | SER | Glucagon signaling pathway | 38/1580 | 107/8465 | 2.57e-05 | 3.28e-04 | 2.38e-04 | 38 |
hsa049224 | Colorectum | MSS | Glucagon signaling pathway | 39/1875 | 107/8465 | 5.00e-04 | 3.45e-03 | 2.11e-03 | 39 |
hsa049225 | Colorectum | MSS | Glucagon signaling pathway | 39/1875 | 107/8465 | 5.00e-04 | 3.45e-03 | 2.11e-03 | 39 |
hsa040689 | Esophagus | ESCC | FoxO signaling pathway | 89/4205 | 131/8465 | 1.56e-05 | 7.98e-05 | 4.09e-05 | 89 |
hsa0492214 | Esophagus | ESCC | Glucagon signaling pathway | 64/4205 | 107/8465 | 2.18e-02 | 4.80e-02 | 2.46e-02 | 64 |
hsa0406814 | Esophagus | ESCC | FoxO signaling pathway | 89/4205 | 131/8465 | 1.56e-05 | 7.98e-05 | 4.09e-05 | 89 |
hsa0492215 | Esophagus | ESCC | Glucagon signaling pathway | 64/4205 | 107/8465 | 2.18e-02 | 4.80e-02 | 2.46e-02 | 64 |
hsa040682 | Liver | Cirrhotic | FoxO signaling pathway | 52/2530 | 131/8465 | 9.98e-03 | 3.32e-02 | 2.05e-02 | 52 |
hsa0492221 | Liver | Cirrhotic | Glucagon signaling pathway | 43/2530 | 107/8465 | 1.42e-02 | 4.35e-02 | 2.68e-02 | 43 |
hsa040683 | Liver | Cirrhotic | FoxO signaling pathway | 52/2530 | 131/8465 | 9.98e-03 | 3.32e-02 | 2.05e-02 | 52 |
hsa0492231 | Liver | Cirrhotic | Glucagon signaling pathway | 43/2530 | 107/8465 | 1.42e-02 | 4.35e-02 | 2.68e-02 | 43 |
hsa040684 | Liver | HCC | FoxO signaling pathway | 85/4020 | 131/8465 | 3.99e-05 | 2.16e-04 | 1.20e-04 | 85 |
hsa0492241 | Liver | HCC | Glucagon signaling pathway | 64/4020 | 107/8465 | 6.70e-03 | 1.87e-02 | 1.04e-02 | 64 |
hsa040685 | Liver | HCC | FoxO signaling pathway | 85/4020 | 131/8465 | 3.99e-05 | 2.16e-04 | 1.20e-04 | 85 |
hsa0492251 | Liver | HCC | Glucagon signaling pathway | 64/4020 | 107/8465 | 6.70e-03 | 1.87e-02 | 1.04e-02 | 64 |
hsa040688 | Oral cavity | OSCC | FoxO signaling pathway | 85/3704 | 131/8465 | 7.50e-07 | 4.33e-06 | 2.21e-06 | 85 |
hsa0406813 | Oral cavity | OSCC | FoxO signaling pathway | 85/3704 | 131/8465 | 7.50e-07 | 4.33e-06 | 2.21e-06 | 85 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRMT1 | deletion | Frame_Shift_Del | c.945delN | p.Val316CysfsTer8 | p.V316Cfs*8 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||||
PRMT1 | SNV | Missense_Mutation | rs544334510 | c.562N>A | p.Asp188Asn | p.D188N | protein_coding | tolerated(0.34) | benign(0.007) | TCGA-DS-A0VM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
PRMT1 | SNV | Missense_Mutation | c.584G>A | p.Arg195Gln | p.R195Q | protein_coding | tolerated(0.06) | probably_damaging(0.999) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | ||
PRMT1 | SNV | Missense_Mutation | c.896N>T | p.Thr299Ile | p.T299I | protein_coding | tolerated(1) | benign(0.139) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | ||
PRMT1 | SNV | Missense_Mutation | c.536N>G | p.Tyr179Cys | p.Y179C | protein_coding | deleterious(0) | possibly_damaging(0.837) | TCGA-D5-6541-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | ||
PRMT1 | SNV | Missense_Mutation | novel | c.298G>A | p.Gly100Ser | p.G100S | protein_coding | deleterious(0.04) | benign(0.308) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
PRMT1 | SNV | Missense_Mutation | novel | c.1015C>T | p.Pro339Ser | p.P339S | protein_coding | deleterious(0.03) | possibly_damaging(0.822) | TCGA-A5-A0GG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PRMT1 | SNV | Missense_Mutation | c.985G>A | p.Glu329Lys | p.E329K | protein_coding | deleterious(0.01) | probably_damaging(0.938) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | ||
PRMT1 | SNV | Missense_Mutation | novel | c.90A>T | p.Glu30Asp | p.E30D | protein_coding | tolerated(0.43) | benign(0.001) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD | |
PRMT1 | SNV | Missense_Mutation | c.1021N>A | p.Ala341Thr | p.A341T | protein_coding | tolerated(0.12) | benign(0.006) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3276 | PRMT1 | ENZYME, METHYL TRANSFERASE | FURAMIDINE | FURAMIDINE | 24564570 | |
3276 | PRMT1 | ENZYME, METHYL TRANSFERASE | NSC-45174 | CHEMBL221047 | 20666457 | |
3276 | PRMT1 | ENZYME, METHYL TRANSFERASE | inhibitor | 310264736 | ||
3276 | PRMT1 | ENZYME, METHYL TRANSFERASE | inhibitor | 178103616 | ||
3276 | PRMT1 | ENZYME, METHYL TRANSFERASE | inhibitor | 178103608 | ||
3276 | PRMT1 | ENZYME, METHYL TRANSFERASE | inhibitor | 178103607 | ||
3276 | PRMT1 | ENZYME, METHYL TRANSFERASE | STILBAMIDINE | STILBAMIDINE | 20666457 | |
3276 | PRMT1 | ENZYME, METHYL TRANSFERASE | NSC-47762 | CHEMBL1092740 | 20666457 | |
3276 | PRMT1 | ENZYME, METHYL TRANSFERASE | EOSIN | EOSIN | 18348515 |
Page: 1 |